Immunotope Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Latest Deal Type
-
Grant
- Financing Rounds
-
3
Immunotope General Information
Description
Developer of immunotherapy products created for the treatment and prevention of cancer and chronic viral infections. The company's immunotherapy platform provides the ideal combination of technologies for successful immunotherapy, use the exquisite sensitivity and specificity of the immune system for early detection of cancer, provide innovative tools and services for collaborative development of novel drug and diagnostic products, enabling patients with effective treatments that destroy tumors and prevent metastasis.
Contact Information
Website
www.immunotope.com(Operating Subsidiary)
Corporate Office
- The Pennsylvania Biotechnology Center
- 3805 Old Easton Road
- Doylestown, PA 18902
- United States
Corporate Office
- The Pennsylvania Biotechnology Center
- 3805 Old Easton Road
- Doylestown, PA 18902
- United States
Immunotope Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Immunotope Comparisons
Industry
Financing
Details
Immunotope Competitors (49)
One of Immunotope’s 49 competitors is Dendreon, a Formerly VC-backed company based in Seal Beach, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dendreon | Formerly VC-backed | Seal Beach, CA | ||||
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Virometix | Venture Capital-Backed | Schlieren, Switzerland | ||||
| Xenetic Biosciences | Corporation | Framingham, MA | ||||
| Amal Therapeutics | Formerly VC-backed | Geneva, Switzerland |
Immunotope Patents
Immunotope Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2020051566-A1 | Vaccines with enhanced immune response and methods for their preparation | Inactive | 07-Sep-2018 | ||
| US-20170119869-A1 | Dengue virus specific multiple hla binding t cell epitopes for the use of universal vaccine development | Active | 13-May-2014 | ||
| WO-2015175361-A1 | Dengue virus specific multiple hla binding t cell epitopes for the use of universal vaccine development | Inactive | 13-May-2014 | ||
| US-20160361410-A1 | Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection | Active | 28-Feb-2014 | ||
| WO-2015130488-A2 | Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection | Inactive | 28-Feb-2014 | A61K39/12 |
Immunotope FAQs
-
When was Immunotope founded?
Immunotope was founded in 2002.
-
Where is Immunotope headquartered?
Immunotope is headquartered in Doylestown, PA.
-
What industry is Immunotope in?
Immunotope’s primary industry is Drug Discovery.
-
Is Immunotope a private or public company?
Immunotope is a Private company.
-
What is Immunotope’s current revenue?
The current revenue for Immunotope is .
-
Who are Immunotope’s competitors?
Dendreon, AnTolRx, Virometix, Xenetic Biosciences, and Amal Therapeutics are some of the 49 competitors of Immunotope.
-
When was Immunotope acquired?
Immunotope was acquired on 16-Jul-2010.
-
Who acquired Immunotope?
Immunotope was acquired by IMV (Canada).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process